Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 4/20 | 0.81 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.81 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.81 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.81 |
| ▸ | MEN1 | O00255 | 6/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.63 |
| ▸ | MTOR | P42345 | 1/20 | 0.62 |
| ▸ | PRKDC | P78527 | 1/20 | 0.62 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.62 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 10/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | TNF | P01375 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.54 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL188557 | 0.93 | PIK3CD (0.84) | PIK3CDPIK3CAPIK3CGPIK3CBMEN1 | |
| SCHEMBL188977 | 0.92 | PIK3CG (0.87) | PIK3CDPIK3CAPIK3CGPIK3CBMEN1 | |
| SCHEMBL2301857 | 0.90 | PIK3CD (0.83) | PIK3CDPIK3CAPIK3CGPIK3CBMEN1 | |
| SCHEMBL188903 | 0.90 | PIK3CG (1.00) | PIK3CDPIK3CAPIK3CGPIK3CBMEN1 | |
| SCHEMBL6996405 | 0.90 | PIK3CD (0.83) | PIK3CDPIK3CAPIK3CGPIK3CBMEN1 | |
| SCHEMBL189089 | 0.90 | PIK3CD (0.83) | PIK3CDPIK3CAPIK3CGPIK3CBMEN1 | |
| SCHEMBL2301901 | 0.89 | PIK3CD (0.81) | PIK3CDPIK3CAPIK3CGPIK3CBMEN1 | |
| SCHEMBL14050703 | 0.89 | PIK3CD (0.81) | PIK3CDPIK3CAPIK3CGPIK3CBMEN1 | |
| SCHEMBL189609 | 0.89 | PIK3CD (0.81) | PIK3CDPIK3CAPIK3CGPIK3CBMEN1 | |
| SCHEMBL188669 | 0.89 | PIK3CD (0.81) | PIK3CDPIK3CAPIK3CGPIK3CBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140100215-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2014-04-10 | — | — | US | claimed |
| US-20120302545-A1 | Method of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2012-11-29 | — | — | US | claimed |
| EP-2056829-B9 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS INC (US) | 2012-09-26 | — | — | EP | claimed |
| EP-2056829-B1 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS INC (US) | 2012-01-04 | — | — | EP | claimed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | claimed |
| EP-2056829-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | Exelixis, Inc. (US) | 2009-05-13 | — | — | EP | claimed |
| WO-2008021389-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS, INC. (US) | 2008-02-21 | — | — | WO | claimed |
| US-20140100215-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| US-8642584-B2 | Method of using PI3K and MEK modulators | EXELIXIS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642584-B2 | Method of using PI3K and MEK modulators | EXELIXIS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642584-B2 | Method of using PI3K and MEK modulators | EXELIXIS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120302545-A1 | Method of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| EP-2056829-B9 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS INC (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2056829-B1 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS INC (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | PIK3CD 2/4885PIK3CA 1/4885PIK3CG 5/4885 |
| US-20140100215-A1 | Methods of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | PIK3CD 2/4885PIK3CA 1/4885PIK3CG 5/4885 |
| US-20120302545-A1 | Method of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | PIK3CD 2/4885PIK3CA 1/4885PIK3CG 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.